Interleukin 10 gene rs1800896 polymorphism is associated with the risk of prostate cancer
Metrics: PDF 959 views | HTML 2119 views | ?
Hao Chen1, Jilei Tang2, Nan Shen3 and Kewei Ren4
1Department of Urology, The First Hospital of Jiaxing, Jiaxing 314001, China
2Department of Orthopedics, Qidong People’s Hospital, Nantong 226200, China
3Department of Clinical Pharmacy, The Affiliated Jiangyin Hospital of Southeast University Medical School, Jiangyin 214400, China
4Department of Orthopedics, The Affiliated Jiangyin Hospital of Southeast University Medical School, Jiangyin 214400, China
Kewei Ren, email: [email protected]
Keywords: interleukin-10, polymorphism, prostate cancer, meta-analysis
Received: May 10, 2017 Accepted: June 30, 2017 Published: August 03, 2017
Numerous studies have uncovered the association of Interleukin-10 (IL-10) gene rs1800896 polymorphism with the risk of prostate cancer (PCa); however, their conclusions were inconsistent. Therefore, we conducted this meta-analysis to evaluate the role of IL-10 rs1800896 polymorphism in the risk of PCa. 16 eligible studies in 15 articles involving 6,301 cases and 6,510 controls were identified by researching PubMed, Google, CNKI, and EMBASE up to April 1, 2017. Our results revealed that IL-10 rs1800896 polymorphism was associated with the decreased risk of PCa under the homozygous model. Subgroup analysis by ethnicity revealed that rs1800896 polymorphism decreased the risk of PCa among Caucasians. In conclusion, IL-10 gene rs1800896 polymorphism is associated with the decreased risk of PCa. Larger studies with more diverse ethnic populations are needed to confirm these results.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.